Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/65281
Title: High prevalence of autoantibodies to RNA helicase A in Mexican patients with systemic lupus erythematosus
Author: Vazquez-Del Mercado, M.
Palafox-Sanchez, C.A.
Munoz-Valle, J.F.
Orozco-Barocio, G.
Oregon-Romero, E.
Navarro-Hernandez, R.E.
Salazar-Paramo, M.
Armendariz-Borunda, J.
Gamez-Nava, J.I.
Gonzalez-Lopez, L.
Chan, J.Y.F.
Chan, E.K.L.
Satoh, M.
Issue Date: 2010
Abstract: Introduction: Autoantibodies to RNA helicase A (RHA) were reported as a new serological marker of systemic lupus erythematosus (SLE) associated with early stage of the disease. Anti-RHA and other autoantibodies in Mexican SLE patients and their correlation with clinical and immunological features were examined.Methods: Autoantibodies in sera from 62 Mexican SLE patients were tested by immunoprecipitation of 35S-labeled K562 cell extract and enzyme-linked immunosorbent assay (anti-U1RNP/Sm, ribosomal P, β2GPI, and dsDNA). Anti-RHA was screened based on the immunoprecipitation of the 140-kDa protein, the identity of which was verified by Western blot using rabbit anti-RHA serum. Clinical and immunological characteristics of anti-RHA-positive patients were analyzed.Results: Anti-RHA was detected in 23% (14/62) of patients, a prevalence higher than that of anti-Sm (13%, 8/62). Prevalence and levels of various autoantibodies were not clearly different between anti-RHA (+) vs. (-) cases, although there was a trend of higher levels of anti-RHA antibodies in patients without anti-U1RNP/Sm (P = 0.07). Both anti-RHA and -Sm were common in cases within one year of diagnosis; however, the prevalence and levels of anti-RHA in patients years after diagnosis did not reduce dramatically, unlike a previous report in American patients. This suggests that the high prevalence of anti-RHA in Mexican patients may be due to relatively stable production of anti-RHA.Conclusions: Anti-RHA was detected at high prevalence in Mexican SLE patients. Detection of anti-RHA in races in which anti-Sm is not common should be clinically useful. Racial difference in the clinical significance of anti-RHA should be clarified in future studies. © 2010 Vázques-Del Mercado et al; licensee BioMed Central Ltd.
URI: http://hdl.handle.net/20.500.12104/65281
Appears in Collections:Producción científica UdeG (prueba)

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.